America’s largest banks are on the way to close the year 2025 with historic stock prices, strengthening balance sheets and regulatory freedom, per a Yahoo! Finance report — and investors in banking ETFs are taking notice. • JPMorgan Chase stock is showing upward bias. Where is JPM stock headed?Bank stocks are performing well as compared to other stocks in the market.One major gauge that follows the largest lenders in the country is the KBW Bank Index (BKX), which is up 30% year to date, outperforming the S& ...

Over the past month, ConocoPhillips ( COP ) has not only outperformed the broad energy sector as represented by the State Street® Energy Select Sector SPDR® ETF ( XLE ), but also the S&P 500 and Nasdaq-100 (see chart below). Given that theMichael Fitzsimmons is a retired electronics engineer and avid investor. He advises investors to construct a well-diversified portfolio built on a core foundation of a high-quality low-cost S&P500 fund. For investors who can tolerate short-term risks, he advises an over-we ...

Elevating the perspectives of women leaders and experts shaping global finance, driving decisions on capital allocation and advancing the conversation across the industry.✉️ Subscribe to our Women, Money & Power Report newsletter: https://t.co/58XNV1RuVb https://t.co/fE42WfO8qz ...

Elevating the perspectives of women leaders and experts shaping global finance, driving decisions on capital allocation and advancing the conversation across the industry.✉️ Subscribe to our Women, Money & Power Report newsletter: https://t.co/58XNV1RuVb https://t.co/lzyWVl2csW ...

Elevating the perspectives of women leaders and experts shaping global finance, driving decisions on capital allocation and advancing the conversation across the industry.✉️ Subscribe to our Women, Money & Power Report newsletter: https://t.co/58XNV1RuVb https://t.co/yG4tHzxNZu ...

FULL TALK: @smyyguy from @Blockworks_ introduces Lightspeed IR, their new hub for Solana capital allocators. https://t.co/yxL5MpbHd7 ...

Capital allocators of size can apply and join the waitlist for a Q1 launch:https://t.co/fxQj8yRDSP ...

Our capital allocator stage is now live streaming on @capitalmarkets.Hear from crypto's investing luminaries on macro and everything that's ahead for the industry.Capital Markets (@capitalmarkets):LIVE from Solana Breakpoint 2025: Lock InThe exclusive stream for capital allocators, funds, and financial decision makers.https://t.co/gZx1h9DgpA ...

RT Capital Markets (@capitalmarkets)LIVE from Solana Breakpoint 2025: Lock InThe exclusive stream for capital allocators, funds, and financial decision makers.https://t.co/gZx1h9DgpA ...

Company Overview and Strategy - Azenta is uniquely positioned for strong top-line growth, margin expansion, and inorganic growth opportunities[15] - The company estimates a current serviceable addressable market (SAM) of approximately $6 billion across SMS and Multiomics[18] - Azenta's FY25 revenue was $594 million, with approximately 55% recurring revenue and 3% organic year-over-year growth[26] Sample Management Solutions (SMS) - SMS FY'25 revenue was approximately $325 million, with approximately 50% recurring revenue[85] - The SMS business has experienced a 15%+ CAGR in sample storage growth from FY'15 to FY'25[85] - The company estimates SMS has approximately 11% market share of a $3 billion serviceable addressable market[18, 88] Multiomics (GENEWIZ) - Multiomics (GENEWIZ) FY'25 revenue was approximately $269 million, with over 70% of revenue from returning customers[132] - The company estimates Multiomics has approximately 9% market share of a $3 billion serviceable addressable market[18, 137] - GENEWIZ has sequenced 15 petabytes (PB) of data and synthesized 425 million nucleotides[128] Financial Targets and Capital Allocation - The company is targeting cumulative free cash flow generation of $200 million - $250 million from FY2026 to FY2028[172] - Azenta has a $250 million share repurchase authorization[61] - The company is introducing 2028 organic financial targets including $700 million - $750 million in revenue, 6% - 8% CAGR, 70% recurring revenue, $120 million - $150 million adjusted EBITDA, and 18% - 20% adjusted EBITDA margin[186]